Zai Lab (ZLAB) Competitors

Zai Lab (NASDAQ:ZLAB) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Do analysts recommend ZLAB or GMAB?

Zai Lab currently has a consensus target price of $57.22, indicating a potential upside of 68.31%. Genmab A/S has a consensus target price of $37.60, indicating a potential upside of 54.00%. Given Zai Lab's stronger consensus rating and higher possible upside, equities analysts clearly believe Zai Lab is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Which has higher earnings & valuation, ZLAB or GMAB?

Genmab A/S has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$398.99M	9.46	-$257.10M	-$2.04	-16.66
Genmab A/S	$3.12B	5.02	$1.14B	$1.99	12.27

Does the media refer more to ZLAB or GMAB?

In the previous week, Zai Lab had 6 more articles in the media than Genmab A/S. MarketBeat recorded 16 mentions for Zai Lab and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Zai Lab's score of 0.82 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in ZLAB or GMAB?

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is ZLAB or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to Zai Lab's net margin of -49.68%. Genmab A/S's return on equity of 21.03% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-49.68%	-27.32%	-18.85%
Genmab A/S	37.53%	21.03%	16.98%

Which has more volatility & risk, ZLAB or GMAB?

Zai Lab has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Summary

Genmab A/S beats Zai Lab on 10 of the 17 factors compared between the two stocks.